An Evaluation of MSDC-0160, a Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer's Disease.
Current Alzheimer Research, June 2014
R C Shah, D C Matthews, R D Andrews, A W Capuano, D A Fleischman, J T VanderLugt, J R Colca, Shah RC, Matthews DC, Andrews RD, Capuano AW, Fleischman DA, VanderLugt JT, Colca JR, Raj C Shah, Dawn C Matthews, Randolph D Andrews, Ana W Capuano, Debra A Fleischman, James T VanderLugt, Jerry R Colca
Alzheimer's disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD.MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients.
|Members of the public||3||75%|
|Readers by professional status||Count||As %|
|Student > Ph. D. Student||11||25%|
|Student > Master||8||18%|
|Student > Postgraduate||5||11%|
|Student > Bachelor||3||7%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||13||30%|
|Agricultural and Biological Sciences||9||20%|